Epibiotech dermal papilla cell therapy
The patient's own dermal papilla cells, multiplied in a lab and injected back into the scalp.
- Developed by
- Epibiotech
- Current phase
- Phase 1/2
- Indications
- Androgenetic alopecia
- Also known as
- EPI-001, Stemore
- Last public activity
- June 2026
- Record confidence
- Medium
A combined safety and early-efficacy study.
How it is meant to work
Dermal papilla cells are the follicle's instruction set — they tell surrounding tissue to build a hair. Take a small biopsy, expand those cells in culture, put them back where follicles have miniaturised, and in principle you restore the signal that has been lost.
Development history
- Phase 1Phase 1/2
Registered on ClinicalTrials.gov as NCT07618195: Study of EPI-001 in Patients With Androgenetic Alopecia
ClinicalTrials.gov ↗
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
Study of EPI-001 in Patients With Androgenetic Alopecia
Epibiotech · n=42 · January 2026
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- Study of EPI-001 in Patients With Androgenetic Alopecia — ClinicalTrials.gov